Introduction
Pim2 is a member of the Pim family of serine threonine kinases and is expressed mainly in the hematopoietic system. 1 Functionally, it is described as an antiapoptotic protein, which phosphorylates BAD at serine112 and reverses its apoptotic effects. 2, 3 Pim2-deficient mice are phenotypically normal and display minimal to no defects in hematopoiesis. 4 However, deletion of all three Pim proteins (Pim1, Pim2, Pim3) in mice reduced their growth. 4 Transgenic mice overexpressing Pim2 alone do not show any hematopoietic malignancies. 5, 6 However, we and others have shown that Pim2 can cooperate with other oncogenes to induce malignant transformation. 7 For example, Pim2
has been shown to cooperate with c-myc and Akt to induce lymphoid tumors.
5, 6
Flt-3-ITD is a mutated form of Flt3 that is expressed in 30% of patients with acute myeloid leukemia (AML) and induces transformation of myeloid cells in vitro and in vivo. [8] [9] [10] The expression of Pim2 is transcriptionally induced by Flt3-ITD via STAT5.
11
Also, many AML patients show increased expression of Pim2 regardless of the presence of Flt3-ITD mutations. 11 Moreover, we have shown that Pim2 complements the Flt3-D835Y mutant receptor for myeloid cell transformation, 7 suggesting that Pim2 coexpression together with Flt3Wt or partially transforming Flt3D835Y receptor mimics the transformation induced by Flt3ITD. Together, these data indicate that Pim2 might play an important role in the pathogenesis of leukemia.
The PML-RARα (PRα) fusion protein is the result of a translocation t(15;17)(q22;q11 .2) that is present in the vast majority of acute promyelocytic leukemia (APL) cases. 12 It has been proposed that PRα acts in a dominant-negative fashion to suppress the normal function of both PML and RARα. 13, 14 Mouse models and cell culture experiments have
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From demonstrated that PRα contributes to the leukemic phenotype mainly by inhibiting differentiation of hematopoietic progenitor cells. [15] [16] [17] Data from mouse models indicate that the PRα fusion protein is necessary but not sufficient to induce AML. [18] [19] [20] [21] [22] Both transgenic and knock-in mouse models of PRα induce an AML-like disease after a long latency. 20, 23, 24 The long latency, and additional cytogenetic changes accompanying disease progression in these mice strongly suggest that additional alterations are required for the development of AML by PRα. [25] [26] [27] [28] When Flt3-ITD was overexpressed in PRα cells and these cells were transplanted into wild type recipients, all mice developed APL after a short latency. 29 This is in-line with the genetic and epidemiological data that suggest Flt3-ITD as a second event in the pathogenesis of APL. 30 We therefore hypothesized that Pim2, being an important target of Flt3-ITD, should be able to induce leukemia in mice if overexpressed in PRα cells. We were also interested to see whether there is a difference in the disease latency, penetrance, and phenotype. In order to investigate the role of Pim2 as a cooperative oncogene to PRα in the pathogenesis of leukemia, we performed bone marrow transplantation experiments using Pim2-transduced PRα knock-in (PRα-ki) cells.
Our data demonstrate that Pim2 cooperates with PRα to induce APL in mice after a short latency. The disease was transplantable into secondary and tertiary recipients.
Interestingly, high Pim2 expression was observed in APL patients suggesting a possible cooperative role in inducing leukemia. We propose that high expression of Pim2 in AML cooperates with other oncogenes such as PRα, which may then lead to the development of leukemia.
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Materials and Methods

Mice
Cathepsin G-PML-RARα (PRα) knock-in mice as described earlier were kindly provided by Dr. Timothy Ley. 24 Female and male PRα ki/ki (C57Bl/6) mice at 8-16 weeks of age were used as donors for retroviral transduction and subsequent bone marrow transplantations. Female B6.SJLPtprca Pep3b/BoyJ (SJL, CD45.1+) mice (purchased from Charles River, Belgium) at 8-10 weeks of age were used as recipients for the bone marrow transplantation experiments. All animals were housed under pathogen-free conditions, and all experiments were conducted with the ethical approval of the University Hospital of Muenster Animal Experiment facility.
Pim2-PMY retroviral vector and preparation of Retroviruses
Pim2 was expressed from a retroviral construct that also contained the enhanced green fluorescence (EGFP) coding sequence expressed from an internal ribosomal entry site (IRES) in the PMY vector. The EGFP-PMY vector was a kind gift from Dr. T. Kitamura from The University of Tokyo, Tokyo, Japan. 31 The cDNA for murine Pim2 was amplified and cloned into the pEntry vector for the gateway system using the TOPO-TA directional cloning kit following the manufacturer´s instructions (Invitrogen). The PMY destination vector was made by cloning a gateway cassette into EGFP-PMY at XhoI and ScaII sites. The Pim2 cDNA was then switched from the pEntry vector into the PMY destination vector by a recombination reaction catalyzed by LR-Clonase (Invitrogen). For preparation of retroviruses, the ecotropic packaging cells PlateE were transiently transfected by PMY or PMY-Pim2 using Lipofectamine with Plus reagent (Invitrogen).
Between 24 and 96 hrs after transfection, the retroviral particle-containing supernatants
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Primary BM cell isolation, retroviral transduction and bone marrow transplantation (BMT)
Primitive mouse bone marrow cells were isolated from long bones of healthy, age matched PRα ki mice and were pooled for lineage depletion. Hematopoietic progenitor cells (HPC) were purified by phenotype-sort by using a lineage cell depletion kit for mouse (Miltenyi Biotech, Bergisch-Gladbach, Germany) following the manufacturer´s instructions. Purified 2x10 6 HPC per ml were preincubated overnight in 20%FCS/IMDM (Gibco) supplemented with 10 ng/ml murine IL-3, 5 ng/ml murine IL-6 and 50 ng/ml of murine SCF (Peprotech, UK). Retronectin (Takara, Japan) coating (50μg/ml) was utilized to concentrate the viral particles in the culture dishes and prestimulated PRα BM cells were incubated overnight in these plates. The transduction procedure was repeated three times. The transduction efficiency as measured by EGFP fluorescence was 32% and 35%
for PMY and Pim2-PMY respectively. A total of 3x10 5 EGFP positive cells without any preselection together with 1x10 5 wild type BM cells from B6.SJL mouse were injected into the lateral tail vein of lethally irradiated (10 Gy) B6.SJL-CD45.1 mice. Cotrim was given in the drinking water for 2-3 weeks after BMT. For secondary and tertiary transplantations, mice were lethally irradiated (10 Gy) and transplanted with 1 x 10 6 bone marrow or spleen cells from primary or secondary transplanted mice respectively together with 1x10 5 wild type BM cells.
Analysis of Leukemia development in transplanted mice
To determine the incidence of leukemia in the transplanted mice, cohorts of each transplanted construct were followed over time. To screen for leukemia development, peripheral blood was drawn by retro-orbital plexus bleeding at 4 -5 week intervals.
Animals that became moribund were killed, and blood, BM and spleen samples were analyzed for evidence of leukemia, using automated complete blood count analyses, morphology, flow cytometry, and histopathologic analysis.
Flow Cytometry
Freshly harvested hematopoietic tissue cells (Peripheral blood, BM and Spleen) were suspended in 1%FCS/PBS. The erythrocytes were lysed by alkaline lysis using AKC lysis buffer (0.15M NH 4 Cl, 1mM KHCO 3 , 0.1mM Na-EDTA, pH=7.4). The nucleated cells were then stained by using fluorescence-labeled antibodies to Gr1, Mac1, CD34, B220, CD19, CD3, Ter119, Sca1 or isotype controls (Becton Dickinson). The flow cytometry data were collected by using a BD FACSCalibur, and data were analyzed using CellQuest software (Becton Dickinson). For costaining of Gr1 and CD34 surface markers, the cells from bone marrow or spleen of diseased mice were incubated with Gr1-PE (1:500 diluted) and CD34-APC antibody for 20 min in the dark. After a subsequent wash, cells were acquired by using a FACSAria instrument and data were analyzed by Cell quest and FlowJo software. For analysis of CD34 and Gr1, live cells (DAPI negative) were gated for CD45.2 + (donor cells) and subsequent percentages of cells positive for CD34 and or Gr1 were calculated.
Real time quantitative RT-PCR
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The cDNA was diluted to 200 μl with ddH2O, and 2.5 μl were used for each PCR reaction. The quantitation of mRNA levels was performed by using a real time fluorescence detection method as described earlier.
32 Relative gene expression levels were calculated using standard curves generated by the serial dilutions of cDNA from mouse myeloid progenitor 32D cells. All samples were independently analyzed at least twice for each gene. The housekeeping gene Gapdh served as an additional control for the cDNA quality. Primer and Probe sequences for murine Pim2 were Forward 5´-CGGAACCGTGTGCTAGGCT-3´, Reverse 5´-AGCAGCGCAACCTCAAGTG-3´ and Probe 5´-CCACCGTGTCAGACTCAGTCACCTGC-3´. For detection of the PRα transcript, primers and probes specific for PML-RARα were used. The sequences were Forward primer 5´-TCTTCCTGCCCAACAGCAA-3´, Reverse primer 5´-GCTTGTAGATGCGGGGTAGAG-3´ and probe 5´AGTGCCCAGCCCTCCCTCGC-3´.
MMP-9 primers were used as described 24 .
For the detection of Pim2 expression in human cells, the primers and probe sequences were Forward 5´ CATCAAAGTGATTCCCCGGA-3´, Reverse 5´-TGGGCATGTGACTGAGTCTGA-3´ and Probe 5´ TGTGCTGGGCTGGTCCCCCTT-3´. All probes were FAM and TAMRA labeled. The primary APL samples were from the Dresden study group. The RNA from APL patients and controls were isolated by the trizol method and cDNA was synthesized as described before. 32 The Pim2 expression levels were calculated by the ddCt method using GAPDH gene as control [2^( CtGAPDHCtPim2) ]. Informed consent was obtained from all patients and controls.
Statistical analysis of clinical data
The primary expression data from AML patients were provided by Dr. J.M. Valk, and Dr.
Ruud Delwel (Erasmus University Medical Center, Rotterdam, Netherlands). 33 All the statistical calculations were done by using SPSS.17 software.
Colony assay and ATRA experiment
Freshly isolated BM cells from leukemic or control mice were either seeded (5x10 3 cells)
in methylcellulose with cytokines (Stem cell technology) in the presence of 1μM ATRA or ethanol or incubated in liquid culture in the complete IMDM medium in the presence or absence of ATRA (1μM). RNA was isolated 48 hrs later from liquid cultured cells by the Trizol method followed by cDNA synthesis and qPCR for MMP9 expression as described above. Colonies were counted on day 8. For morphology assessment, cytospins from either liquid culture or from colony assays were prepared and the cells subsequently stained using Wright-Giemsa staining.
Southern blot analysis
Genomic DNA (10 µg) isolated from spleens was digested with HindIII or SacI for 3 hrs and size separated by agarose gel electrophoresis. DNA was transferred to a Biodyne nylon membrane (Pall Corporation) and hybridized to either a GFP or a cyclinD1 probe radioactively labelled by random priming in the presence of [alpha-32P]-dCTP (50mCi; 100TBq/mMol) using the Deca Label kit (MBI Fermentas) following the manufacturer´s instructions.
Results
High expression of Pim2 is observed in APL patients
Expression of the Pim2 kinase is increased in AML blasts irrespective of the Flt3 
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Pim2-PML-RARα transplanted bone marrow cells induce an APL-like disease in mice
We used PRα knock-in (ki) mice to analyze the cooperation of Pim2, since these mice develop disease after a long latency (6 to 16 months of age) and provide a good congenic system (CD45.1/CD45.2) to differentiate donor from recipient cells. PRα ki/ki lineage depleted bone marrow (BM) cells were infected with PMY-Pim2 or control-PMY retroviruses and transplanted into lethally irradiated C57Bl6 Ly5.1 mice. The transduction efficiency for both constructs was comparable (32-37%) ( Figure 2A ). In total, 300,000 GFP positive cells were transplanted into each recipient. In two independent experiments, the coexpression of Pim2 in PRα cells (Pim2-PRα) induced an APL-like phenotype in 64% of the mice (9/14). These Pim2-PRα mice developed disease after a short latency (6 to 18 weeks). None of the mice from the control groups (empty vector transduced PRα n=14, or Pim2 alone n=5) developed full disease ( Figure 2B ). In some mice transplanted with PRα bone marrow that had been transfected with GFP, we did see high neutrophil counts and splenomegaly. However, none of them met the criteria for a leukemic phenotype, which we defined on the basis of splenomegaly, infiltration of organs (spleen, liver, and lung) and the presence of CD34-positive cells in peripheral blood, spleen and bone marrow, and which we found in the Pim2-PRα mice.
Overexpression of Pim2 led to the expansion of GFP positive cells in Pim2-PRα mice shortly before the mice became leukemic in comparison to controls ( Figure 2C ).
Splenomegaly was observed only in Pim2-PRα mice ( Figure 2D ). Donor cells (CD45 .2) were detected in peripheral blood (PB), BM, and spleen of recipient mice, regardless of whether they were transfected with Pim2 ( Figure 3A ). The residual recipient hematopoiesis was largely supplanted by donor hematopoiesis in the Pim2-PRα We next analyzed, whether the disease induced by Pim2PRα is recapitulating the previously described APL phenotype in PRα ki mice. 24 PRα ki primary mice (not transplanted), which became leukemic after 11 months were compared to Pim2PRα transplanted animals. We performed immunophenotypic analysis to detect coexpression of Gr1 and CD34 on bone marrow and spleen cells. As shown in Figure 5 
Pim2-PRα induced leukemias are transplantable in secondary and tertiary recipients
To test directly whether Pim2 coexpression with PRα might confer enhanced leukemogenic potential to bone marrow cells, we assessed the ability of Pim2-PRα transduced BM cells from preleukemic mice to repopulate secondary recipients. For this purpose, a total of 1x10 6 BM or spleen cells (CD45.2 + ) from diseased primary recipients (Pim2-PRα) were tail-vein injected into lethally irradiated congenic mice (CD45.1 + ). As already noted, primary control mice (GFP-PRα) did not develop full-blown disease.
However, we harvested the bone marrow from primary control mice (that were transplanted at the same time as Pim2-PRα mice) and transplanted it into secondary recipients for control purposes. After 9 weeks, all mice transplanted with Pim2-PRα cells from primary diseased recipients developed an APL-like disease ( Figure 6 ). Pim2-PRα Southern blot analyses showed that the disease in the majority of Pim2PRα primary recipients was clonal to oligoclonal (lane 1 to 4, Figure 6D ). When used for secondary transplantation experiments (lane1), one of the subclones grew up as a dominant clone with multiple integration sites (lane 5-6, Figure 6D ). These data provide evidence that clonal selection occurred during serial transplantation of the disease.
Spleen cells from diseased mice express Pim2 and PML-RARα
The mRNA expression of Pim2 and PRα was analyzed in the spleen cells from transplanted mice by real time RT-PCR. As depicted in Figure 6E , PRα was equally expressed in spleen cells from recipients of either Pim2-PRα or Control-PRα cells at Figure 7C ). These data show that the leukemia induced due to Pim2 overexpression in cooperation with PRα is similar to the previously described PML-RARα-induced APL disease in mice. While the latency of the disease was comparably short, penetrance was not complete (9/14 animals, Figure 2B ). Southern blot analyses showed that the disease was oligoclonal. Also, the analysis of primary transplanted mice 4 weeks and 8 weeks after transplantation revealed expansion of the GFP-positive clone only shortly before the mice Figure S1) . Thus, Pim2 expression in the presence of PML-RARα does not induce a rapid polyclonal expansion of leukemic progenitor cells.
Rather, we think that Pim2 might act relatively late in the course of leukemic transformation, still requiring a process of clonal evolution.
However, Pim2 enhanced the probability of successful leukemia development and Pim2 strictly required the presence of PRα in order to induce leukemia. None of the control mice developed a disease, even after prolonged observation. Interestingly, the control transplants expressing PRα, but not Pim2, induced some increase in blood cell counts.
However, in these mice the recipient bone marrow was never completely lost, the mice never became obviously leukemic and were not killed by the increase of their white blood cell counts. Also, when we analyzed the GFP-positivity of these mice late after transplantation, it strongly decreased in four of four animals (Supplemental Figure S1 ).
Taken together, the data imply that Pim2 cooperates with PRα in causing leukemia by enhancing the probability of clonal events that finally induce the leukemic phenotype. Also, they show that in our model, PRα alone cannot successfully compete out the (normal) recipient hematopoiesis, while the double transgenic progenitor cells can.
Once the leukemia was established, it was readily transplantable onto secondary and tertiary recipients (Figure 6 ). Obviously, it was then advantageous to perstistently express both Pim2 and PRα, since the expression of both transgenes was not lost in the course of serial transplantation, although further clonal evolution took place (Figure 6 D, E, F) .
PRα alone did not induce any Pim2 expression in (aleukemic) recipient mice ( Figure 6F ).
In order to exclude that this was only due to the fact that PRα did not induce leukemia in
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From this model, we analyzed Pim2 expression in PRα knock-in mice that had become leukemic after a long latency. Here, we did not observe any correlation of Pim2 expression with the leukemic state of these mice (Supplemental Figure S2) . Also, in none of these mice, Pim2 expression was induced more than 5-10 fold in comparison to the other mice. In contrast, in human APL, Pim2 mRNA is highly expressed at levels that exceed the levels in normal CD34-positive progenitors by several logs (Figure 1B) , well beyond the increase of expression that we achieved by retroviral overexpression in our bone marrow models. Therefore, we think that the observed strong overexpression of Pim2 in human APL is independent of PRα and is recapitulated well in our model system. transplanted a rare subpopulation with high leukemia-initiating potential into our secondary and tertiary recipients.
Besides being important for leukemia initiation, does Pim2 overexpression in PRα cells alter sensitivity of the leukemic cells towards ATRA? We analyzed ATRA sensitivity in vitro of APL bone marrow that we obtained from secondary recipients and compared it to the reported ATRA sensitivity of bone marrow of leukemic PRα knock-in mice. As might be expected knowing that human APL cases express high levels of Pim2 and are exquisitely sensitive to ATRA treatment, we did not find any difference in the response of Pim2-PRα bone marrow versus primary leukemic PRα bone marrow to ATRA treatment. Since Pim2 inhibitors are currently being developed preclinically, it will be highly interesting to study their effect on leukemia maintenance in our model in the future.
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In summary, our data show for the first time that Pim2 in cooperation with PML-RARα accelerates leukemia development and provide evidence for a functional role of the observed high Pim2 expression in human APL bone marrow. Our data do not define the mechanism by which Pim2 causes this effect in cooperation with PML-RARα, and further studies are required to investigate the mechanism involved in this. The data indicate that Pim2 might be an important oncogene in AML. It is induced by Flt3 mutations and by other yet unknown mechanisms. As such, Pim kinases constitute potentially attractive therapeutic targets.
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